RWJ 445167
Alternative Names: 3DP 10017; RWJ-445167Latest Information Update: 28 Oct 2019
Price :
$50 *
At a glance
- Originator Johnson & Johnson
- Developer Johnson & Johnson; Zosano Pharma
- Class Antithrombotics; Guanidines
- Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for preclinical development in Thrombosis in USA (Transdermal, Patch)
- 02 Sep 2016 Discontinued - Clinical-Phase-Unknown for Thrombosis (PO)
- 29 Sep 2015 Preclinical trials in Thrombosis in USA (Transdermal)